Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :

or

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :

or

Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InflaRx N.V. IFRX

"InflaRx NV is a clinical-stage biopharmaceutical company is focused on applying proprietary anti-C5a technology to discover and develop specific inhibitors of the complement activation factor known as C5a. The lead product candidate of the company is IFX-1, which is developed for the treatment of Hidradenitis Suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. The company's proprietary anti-C5a technology is an inflammatory mediator involved in the progression of a

View modes: 

$3.15 is a BUY

definitely a buy here, nice accumulation happening, trial updates and new interpretation of anomaly will send this to over $10 in the blink of an eye.  rate and reply

IFRX $3.33 NASDAQ BIOTECH BOUNCE ALERT!

Starting to turn up here. Emotional traders who sold on fear from huge $40++ per share drop on bad news the past few days. This will see a huge bounce. Was $50+ a share not long ago. Company has over ...read more

IFRX $3.20 From $40 Huge Bargain!!

IFRX has millions in cash. This has been manipulated on the over reaction and panic due to failed drug trial. This should see a huge bounce from these lows  rate and reply

it's a buy today for me

bought in at $3.57 per share,seems to be oversold to me,watching the technicals for this one,german biopharma company with a good cash position,so glta.  rate and reply

×

StockTalk
Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.